Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETAL-1: HSCT vs Chemotherapy in Intermediate Risk AML
NCT01246752Phase 3Terminated
- Sponsor
- University Hospital Carl Gustav Carus
- Start
- Feb 2011
- Primary completion
- Apr 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of allogeneic hematopoietic stem cells in acute myeloid leukemia (AML), sponsored by University Hospital Carl Gustav Carus. Started Feb 2011; status: terminated.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01246752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01246752.